AAPL   321.85 (+1.23%)
MSFT   182.83 (-0.23%)
FB   231.91 (+3.03%)
GOOGL   1,434.87 (+0.09%)
AMZN   2,471.04 (+1.17%)
NVDA   352.25 (-0.78%)
CGC   16.48 (-5.12%)
BABA   206.57 (-0.40%)
MU   46.34 (-3.28%)
GE   6.76 (+2.89%)
TSLA   898.10 (+7.56%)
AMD   53.63 (-0.32%)
T   30.93 (+0.23%)
ACB   14.10 (+0.14%)
F   5.87 (+2.80%)
GILD   75.16 (-3.43%)
DIS   118.77 (+1.25%)
NFLX   425.92 (+1.47%)
BAC   24.61 (+2.03%)
BA   151.39 (+3.80%)
AAPL   321.85 (+1.23%)
MSFT   182.83 (-0.23%)
FB   231.91 (+3.03%)
GOOGL   1,434.87 (+0.09%)
AMZN   2,471.04 (+1.17%)
NVDA   352.25 (-0.78%)
CGC   16.48 (-5.12%)
BABA   206.57 (-0.40%)
MU   46.34 (-3.28%)
GE   6.76 (+2.89%)
TSLA   898.10 (+7.56%)
AMD   53.63 (-0.32%)
T   30.93 (+0.23%)
ACB   14.10 (+0.14%)
F   5.87 (+2.80%)
GILD   75.16 (-3.43%)
DIS   118.77 (+1.25%)
NFLX   425.92 (+1.47%)
BAC   24.61 (+2.03%)
BA   151.39 (+3.80%)
AAPL   321.85 (+1.23%)
MSFT   182.83 (-0.23%)
FB   231.91 (+3.03%)
GOOGL   1,434.87 (+0.09%)
AMZN   2,471.04 (+1.17%)
NVDA   352.25 (-0.78%)
CGC   16.48 (-5.12%)
BABA   206.57 (-0.40%)
MU   46.34 (-3.28%)
GE   6.76 (+2.89%)
TSLA   898.10 (+7.56%)
AMD   53.63 (-0.32%)
T   30.93 (+0.23%)
ACB   14.10 (+0.14%)
F   5.87 (+2.80%)
GILD   75.16 (-3.43%)
DIS   118.77 (+1.25%)
NFLX   425.92 (+1.47%)
BAC   24.61 (+2.03%)
BA   151.39 (+3.80%)
AAPL   321.85 (+1.23%)
MSFT   182.83 (-0.23%)
FB   231.91 (+3.03%)
GOOGL   1,434.87 (+0.09%)
AMZN   2,471.04 (+1.17%)
NVDA   352.25 (-0.78%)
CGC   16.48 (-5.12%)
BABA   206.57 (-0.40%)
MU   46.34 (-3.28%)
GE   6.76 (+2.89%)
TSLA   898.10 (+7.56%)
AMD   53.63 (-0.32%)
T   30.93 (+0.23%)
ACB   14.10 (+0.14%)
F   5.87 (+2.80%)
GILD   75.16 (-3.43%)
DIS   118.77 (+1.25%)
NFLX   425.92 (+1.47%)
BAC   24.61 (+2.03%)
BA   151.39 (+3.80%)
Log in

NASDAQ:VBLTVascular Biogenics Stock Price, Forecast & News

$1.23
0.00 (0.00 %)
(As of 06/1/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.17
Now: $1.23
$1.24
50-Day Range
$1.14
MA: $1.29
$1.63
52-Week Range
$0.90
Now: $1.23
$1.64
Volume887,588 shs
Average Volume295,267 shs
Market Capitalization$51.57 million
P/E RatioN/A
Dividend YieldN/A
Beta0.86
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and in Phase III clinical trials for recurrent platinum-resistant ovarian cancer, as well as for Phase II clinical trials for iodine-resistant differentiated thyroid cancer. The company is also developing VB-111, which is in Phase I clinical trials for the treatment of patients with various types of advanced metastatic cancer types, including thyroid cancer, neuroendocrine cancer, renal cell carcinoma, and lung cancer. In addition, it is developing VB-511, an anti-angiogenic candidate for oncology; VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases; VB-201, a Lecinoxoid-based compound for the control of chronic inflammatory disorders; and VB-600 that is in pre-clinical stage for targeting of MOSPD2 for immuno-oncology and anti-inflammatory applications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Modi'in, Israel.
Read More
Vascular Biogenics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.18 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VBLT
Previous SymbolNASDAQ:VBLX
CUSIPN/A
Phone972-8993-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$560,000.00
Book Value$1.00 per share

Profitability

Net Income$-19,460,000.00
Net Margins-2,909.45%

Miscellaneous

Employees38
Market Cap$51.57 million
Next Earnings Date8/11/2020 (Estimated)
OptionableOptionable

Receive VBLT News and Ratings via Email

Sign-up to receive the latest news and ratings for VBLT and its competitors with MarketBeat's FREE daily newsletter.

Vascular Biogenics (NASDAQ:VBLT) Frequently Asked Questions

How has Vascular Biogenics' stock been impacted by COVID-19 (Coronavirus)?

Vascular Biogenics' stock was trading at $1.22 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, VBLT shares have increased by 0.8% and is now trading at $1.23. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Vascular Biogenics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vascular Biogenics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Vascular Biogenics.

When is Vascular Biogenics' next earnings date?

Vascular Biogenics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Vascular Biogenics.

How were Vascular Biogenics' earnings last quarter?

Vascular Biogenics Ltd (NASDAQ:VBLT) posted its earnings results on Thursday, May, 14th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.02. The biopharmaceutical company earned $0.37 million during the quarter, compared to analyst estimates of $0.19 million. Vascular Biogenics had a negative net margin of 2,909.45% and a negative return on equity of 53.61%. View Vascular Biogenics' earnings history.

What price target have analysts set for VBLT?

5 Wall Street analysts have issued twelve-month target prices for Vascular Biogenics' shares. Their forecasts range from $2.50 to $5.00. On average, they anticipate Vascular Biogenics' stock price to reach $3.88 in the next twelve months. This suggests a possible upside of 215.0% from the stock's current price. View analysts' price targets for Vascular Biogenics.

Has Vascular Biogenics been receiving favorable news coverage?

Media headlines about VBLT stock have trended very positive this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Vascular Biogenics earned a media sentiment score of 3.5 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutVascular Biogenics.

Are investors shorting Vascular Biogenics?

Vascular Biogenics saw a increase in short interest in May. As of May 15th, there was short interest totaling 96,800 shares, an increase of 33.7% from the April 30th total of 72,400 shares. Based on an average trading volume of 191,300 shares, the short-interest ratio is currently 0.5 days. Currently, 0.4% of the company's shares are short sold. View Vascular Biogenics' Current Options Chain.

Who are some of Vascular Biogenics' key competitors?

What other stocks do shareholders of Vascular Biogenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include Alibaba Group (BABA), Opko Health (OPK), SCYNEXIS (SCYX), Verastem (VSTM), Rigel Pharmaceuticals (RIGL), vTv Therapeutics (VTVT), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), T2 Biosystems (TTOO) and AEterna Zentaris (AEZS).

Who are Vascular Biogenics' key executives?

Vascular Biogenics' management team includes the following people:
  • Prof. Dror Harats, CEO & Director (Age 63)
  • Mr. Amos Ron, CFO & Company Sec. (Age 65)
  • Dr. Erez Feige, VP of Bus. Operations (Age 46)
  • Dr. Eyal Breitbart, VP of Research & Operations (Age 53)
  • Dr. Naamit Sher, VP of Drug Devel. & Regulatory Affairs (Age 66)

What is Vascular Biogenics' stock symbol?

Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."

Who are Vascular Biogenics' major shareholders?

Vascular Biogenics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Morgan Stanley (1.05%), Advisor Group Holdings Inc. (0.12%) and Envestnet Asset Management Inc. (0.10%).

Which major investors are buying Vascular Biogenics stock?

VBLT stock was bought by a variety of institutional investors in the last quarter, including Advisor Group Holdings Inc., Envestnet Asset Management Inc., and Morgan Stanley.

How do I buy shares of Vascular Biogenics?

Shares of VBLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Vascular Biogenics' stock price today?

One share of VBLT stock can currently be purchased for approximately $1.23.

How big of a company is Vascular Biogenics?

Vascular Biogenics has a market capitalization of $51.57 million and generates $560,000.00 in revenue each year. The biopharmaceutical company earns $-19,460,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. Vascular Biogenics employs 38 workers across the globe.

What is Vascular Biogenics' official website?

The official website for Vascular Biogenics is www.vblrx.com.

How can I contact Vascular Biogenics?

Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The biopharmaceutical company can be reached via phone at 972-8993-5000 or via email at [email protected]

This page was last updated on 6/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.